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Abstract
Background: Buruli ulcer caused by Mycobacterium ulcerans is endemic in parts of West Africa and is most prevalent
among the 5–15 years age group; Buruli ulcer is uncommon among neonates. The mode of transmission and
incubation period of Buruli ulcer are unknown. We report two cases of confirmed Buruli ulcer in human
immunodeficiency virus-unexposed, vaginally delivered term neonates in Ghana.
Case presentation: Patient 1: Two weeks after hospital delivery, a baby born to natives of the Ashanti ethnic group
of Ghana was noticed by her mother to have a papule with associated edema on the right anterior chest wall and
neck that later ulcerated. There was no restriction of neck movements. The diagnosis of Buruli ulcer was confirmed on
the basis of a swab sample that had a positive polymerase chain reaction result for the IS2404 repeat sequence of M.
ulcerans. Patient 2: This patient, from the Ashanti ethnic group in Ghana, had the mother noticing a swelling in the
baby’s left gluteal region 4 days after birth. The lesion progressively increased in size to involve almost the entire left
gluteal region. Around the same time, the mother noticed a second, smaller lesion on the forehead and left side
of neck. The diagnosis of Buruli ulcer was confirmed by polymerase chain reaction when the child was aged 4
weeks. Both patients 1 and 2 were treated with oral rifampicin and clarithromycin at recommended doses for 8
weeks in addition to appropriate daily wound dressing, leading to complete healing. Our report details two cases
of polymerase chain reaction-confirmed Buruli ulcer in children whose lesions appeared at ages 14 and 4 days,
respectively. The mode of transmission of M. ulcerans infection is unknown, so the incubation period is difficult to
estimate and is probably dependent on the infective dose and the age of exposure. In our study, lesions appeared 4
days after birth in patient 2. Unless the infection was acquired in utero, this would be the shortest incubation period
ever recorded.
Conclusions: Buruli ulcer should be included in the differential diagnosis of neonates who present with characteristic
lesions. The incubation period of Buruli ulcer in neonates is probably shorter than is reported for adults.
Keywords: Buruli ulcer, Neonate, Incubation period, Ghana
Background
Buruli ulcer (BU) caused by Mycobacterium ulcerans is
endemic in parts of West Africa [1, 2]. The causative
organism produces the toxin called mycolactone [3],
which has been shown to be cytotoxic to a range of
immune and nonimmune cells [4]. Although the toxin
mediates a predominantly necrotizing cutaneous and
subcutaneous tissue infection, it may occasionally involve
deeper structures such as the bone, causing osteomyelitis.
BU begins as a small, painless, raised skin papule, nodule,
plaque, or edema that becomes indurated, crusted, and
eventually ulcerates. The formation of the characteristic
ulcer results from destruction of the subcutaneous adipose
tissue leading to collapse of the epidermis. Over a period
of weeks, the ulcer enlarges, with widespread thickening of
subcutaneous tissue. Subsequently, there is necrosis that
produces the characteristic undermining of the ulcer
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margins. In larger lesions, there may be extensive indur-
ation adjacent to the ulcer. Beyond this area of thickening,
however, the skin appears normal, with no cellulitis or
lymphadenopathy. Necrosis may extend down to muscle
fascia and even to bone, but actual osteomyelitis is rare.
Advanced lesions display massive tissue destruction and
minimal inflammation, with extracellular microcolonies of
M. ulcerans in the superficial necrotic areas [5, 6]. Charac-
teristically, the lesions are not associated with pain or
tenderness. The disease is rarely fatal but can lead to
significant debilitation as well as enormous social and eco-
nomic consequences in afflicted persons [2]. BU is most
prevalent among the age group 5–15 years but is uncom-
mon among neonates [1]. The exact mode of transmission
and the incubation period of the causative organism of the
disease are not known. We report cases of confirmed BU
disease in two human immunodeficiency virus (HIV)-un-
exposed, vaginally delivered term neonates from the
Ashanti region of Ghana and discuss the implications for
understanding the incubation period of M. ulcerans.
Case presentation
The clinical characteristics of the two patients are
presented in Table 1.
Patient 1
This patient was from the Ashanti ethnic group in Ghana.
Two weeks after hospital delivery, patient 1’s mother
noticed a papule with associated edema on the right
anterior chest wall and neck that later ulcerated and was
associated with fever and poor feeding. Clinical examin-
ation revealed an 11-cm × 7-cm ulcer with undermined
edges on the right anterior chest wall that extended to
involve the right neck and pre- and postauricular regions
and submental regions (Fig. 1). There was no restriction
of neck movements. An initial clinical diagnosis of
necrotizing fasciitis was made, and empiric treatment with
gentamicin was started, based on the local culture and
sensitivity patterns. The ulcer was secondarily infected by
Staphylococcus aureus, which was sensitive to gentamicin.
The diagnosis of BU was confirmed on the basis of a swab
sample that was polymerase chain reaction (PCR)-positive
for the IS2404 repeat sequence of M. ulcerans.
Patient 2
This patient was from the Ashanti ethnic group in Ghana.
The mother of patient 2 reported noticing a swelling in
the baby’s left gluteal region 4 days after birth. The lesion
progressively increased in size to involve almost the entire
left gluteal region. Around the same time, the mother no-
ticed a second, smaller lesion on the forehead and left side
of the neck. The patient had a 6 × 5-cm left gluteal ulcer
with undermined edges, firm base, and floor covered with
slough and purulent discharge (Fig. 2). An initial clinical
diagnosis of necrotizing fasciitis was made, and empiric
treatment with gentamicin was initiated. A wound swab
culture result yielded Escherichia coli, which was sensitive
to gentamicin. The diagnosis of BU was confirmed by
PCR when the child was aged 4 weeks.
Treatment
Both patients were treated with oral rifampicin and
clarithromycin (at doses of 10 mg/kg and 15mg/kg,
respectively) administered daily for 8 weeks in addition
to appropriate daily wound dressing. Antibiotic treat-
ment was well tolerated by both patients. Treatment ad-
herence was monitored using the standard Buruli ulcer
01 (BU 01) form used during the routine care of patients
with BU. Their ulcers healed completely by the end of
antibiotic treatment, but they developed contracted
scars. Surgery to correct the deformities was planned by
a plastic surgeon.
Table 1 Clinical characteristics of two Ghanaian neonates with Buruli ulcer disease
Characteristic Patient 1 Patient 2
Community/region Ejisu, Ashanti Atwima Nwabiagya, Ashanti
Mode and location of delivery Vaginally, hospital Vaginal, home
BCG vaccination Yes Yes
Lesion site Chest and neck Left gluteus, left neck
Type of lesion, WHO category Edema/ulcer, category 2 Ulcer, category 3 (on account of multiple lesions)
Age (in days) when lesion was first seen 14 days 4 days
Age of neonate at PCR confirmation of BU 5 weeks 4 weeks
Use of topical herbs Yes Yes
Temperature 36.3 °C 37.9 °C
Ulcer healing by end of antibiotic treatment Yes Yes
Development of contracture Yes, corrective surgery planned Yes, corrective surgery planned
Organism causing secondary bacterial infection of ulcer Staphylococcus aureus Escherichia coli
BCG Bacille Calmette-Guérin, BU Buruli ulcer, PCR Polymerase chain reaction, WHO World Health Organization
Amoako et al. Journal of Medical Case Reports          (2019) 13:218 Page 2 of 5
Discussion
To the best of our knowledge, there has not been any
previous report of confirmed BU in neonates in Ghana.
Our report details two cases of PCR-confirmed BU in
children whose lesions appeared at age 14 and 4 days,
respectively. BU caused by M. ulcerans is endemic in
parts of West Africa and usually presents as a painless
subcutaneous nodule or plaque or as a more aggressive
edematous lesion. Over time, all the lesions ulcerate and
progressively enlarge. In Africa, the disease is most
prevalent among the age group 5–15 years [1].
The mode of transmission of M. ulcerans infection is
unknown, so the incubation period is difficult to esti-
mate. Studies of people who have become infected after
moving from a nonendemic to an endemic area have
provided some insight into this. The Uganda Buruli
Group studied refugees from Rwanda, where there are
no reported cases, and found new Buruli lesions occur-
ring 4–10 weeks after their arrival from an endemic area
[7]. An incubation period of 6 weeks was estimated in a
Nigerian physician who had visited an endemic area and
later developed BU in New York [8]. In two recent
studies among patients developing BU after a short visit
to an endemic area in Australia, the median incubation
periods were estimated as 135 and 143 days, respectively,
with the shortest period given as 32 days [9, 10]. These
studies provide a fair idea of the possible incubation
period of BU in adults, but in neonates it may range from
a few days to several weeks. A study of 13 cases of BU in
Port Moresby identified the shortest known incubation
period of 2–3 weeks in a 6-week-old baby born in an
endemic region [11]. Cases of BU have been observed in
18-day-old [12] and 9-month-old [13] babies in the
Democratic Republic of Congo and Uganda, respectively.
In the present study, lesions appeared 4 days after
birth in patient 2. Unless infection was acquired in utero,
this would be the shortest incubation period ever
recorded. There was no evidence of BU in the mother,
so it must be assumed that the baby was exposed to an
M. ulcerans-contaminated water source shortly after
birth. Because neither the mothers nor the babies in this
report had HIV infection, the short incubation period
probably resulted from immaturity of the neonatal
immune system. Another explanation would be that the
Fig. 1 Pre- and post-treatment Buruli ulcer (BU) lesion in patient 1. Buruli ulcer located on the anterior chest of patient 1 before BU-specific antibiotic
treatment (a). The ulcer had completely healed after 8 weeks of treatment with rifampicin and clarithromycin in addition to appropriate daily wound
dressings (b)
Fig. 2 Pre- and post-treatment Buruli ulcer (BU) lesion in patient 2. Buruli ulcer on the gluteal region of patient 2 before BU-specific antibiotic
treatment (a). The ulcer had completely healed after 8 weeks of treatment with rifampicin and clarithromycin in addition to appropriate daily
wound dressings (b)
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babies were exposed to a high infection dose, but there
is no way of confirming this.
Bacille Calmette-Guérin (BCG) vaccine was thought to
have a short-term protective effect against M. ulcerans
infection in Uganda [14], and having a BCG vaccination
scar was reported to provide significant protection
against M. ulcerans osteomyelitis [15]. A recent study,
however, did not find significant evidence of a protective
effect of routine BCG vaccination on the risk of develop-
ing either BU or severe forms of BU [16]. The vaccine
used now may not be exactly the same, and certainly it
did not protect the babies in this report, who had both
received it at birth.
Traditionally, combination antibiotic therapy with
intramuscular streptomycin and oral rifampicin for 8
weeks has been used to treat BU disease, and this has
been shown to give excellent cure rates [17, 18]. Due to
the disadvantages of streptomycin [19] (prolonged intra-
muscular injections and risk of ototoxicity), daily oral
treatment with rifampicin and clarithromycin is now
recommended for treatment, especially in children.
There was evidence of symptomatic secondary bacterial
infection in both the patients reported here, with S. aureus
in patient 1 and E. coli in patient 2. This would account
for the fever and poor feeding reported by both mothers
and the systemic signs of infection that are not associated
with BU. However, the ulcers did not start to heal until
specific therapy for M. ulcerans was administered.
Secondary bacterial infections with S. aureus and E. coli
have been reported as common isolates, usually sensitive
to gentamicin, as was the case in our patients [20].
Conclusions
This report presents the first cases of BU in neonates from
Ghana, a BU-endemic country in West Africa. Oral treat-
ment with rifampicin and clarithromycin administered
daily for 8 weeks proved effective in the management of
BU in these neonates, thereby avoiding the use of painful
daily streptomycin injections with their associated ototox-
icity. BU should be included in the differential diagnosis of
neonates who present with characteristic lesions. The
incubation period of BU in this age group is probably
shorter than is reported for adults.
Abbreviations
BCG: Bacille Calmette-Guérin; BU: Buruli ulcer; BU 01: Buruli ulcer 01 form;
HIV: Human immunodeficiency virus; IP: Incubation period; PCR: Polymerase
chain reaction
Acknowledgements
Not applicable.
Authors’ contributions
YAA, MF, and ROP conceived of the case report and its design. DOA, GPR,
EBY, BA, FS, HA, EA, KGD, and MKA participated in data collection and
analysis. KA participated in writing and critically reviewing the manuscript.
YA, MF, MWJ, and ROP wrote the manuscript and reviewed it for important
intellectual content. All authors read, reviewed, and approved the final
version of the manuscript.
Funding
No funding was received for this study.
Availability of data and materials
The datasets obtained and analyzed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
Ethical approval was obtained from the Committee on Human Research,
Publication and Ethics of the School of Medicine and Dentistry of the
Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Consent for publication
Written informed consent was obtained from the patient’s legal guardian(s) for
publication of this case report and any accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Author details
1Komfo Anokye Teaching Hospital, Kumasi, Ghana. 2Kumasi Centre for
Collaborative Research in Tropical Medicine, Kwame Nkrumah University of
Science and Technology, Kumasi, Ghana. 3School of Medicine and Dentistry,
Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
4Agogo Presbyterian Hospital, Agogo, Ghana. 5Global Buruli Ulcer Initiative,
WHO, Geneva, Switzerland. 6Institute of Infection and Immunity, St George’s
University of London, London, UK.
Received: 5 March 2019 Accepted: 4 June 2019
References
1. Amofah GK, Sagoe-Moses C, Adjei-Acquah C, Frimpong EH. Epidemiology of
Buruli ulcer in Amansie West district, Ghana. Trans R Soc Trop Med Hyg.
1993;87(6):644–5.
2. Asiedu K, Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a
three-year review. Am J Trop Med Hyg. 1998;59(6):1015–22.
3. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, et al. Giant
plasmid-encoded polyketide synthases produce the macrolide toxin of
Mycobacterium ulcerans. Proc Natl Acad Sci U S A. 2004;101(5):1345–9.
4. Demangel C, Stinear TP, Cole ST. Buruli ulcer: reductive evolution enhances
pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol. 2009;7(1):50–60.
5. Hayman J. Clinical features of Mycobacterium ulcerans infection. Australas J
Dermatol. 1985;26(2):67–73.
6. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, Asamoa K, et
al. Histopathologic features of Mycobacterium ulcerans infection. Emerg
Infect Dis. 2003;9(6):651–6.
7. Uganda Buruli Group. Epidemiology of Mycobacterium ulcerans infection (Buruli
ulcer) at Kinyara, Uganda. Trans R Soc Trop Med Hyg. 1971;65(6):763–75.
8. Lindo SD, Daniels F Jr. Buruli ulcer in New York City. JAMA. 1974;228(9):1138–9.
9. Loftus MJ, Trubiano JA, Tay EL, Lavender CJ, Globan M, Fyfe JAM, et al. The
incubation period of Buruli ulcer (Mycobacterium ulcerans infection) in
Victoria, Australia remains similar despite changing geographic distribution
of disease. PLoS Negl Trop Dis. 2018;12(3):e0006323.
10. Trubiano JA, Lavender CJ, Fyfe JA, Bittmann S, Johnson PD. The incubation
period of Buruli ulcer (Mycobacterium ulcerans infection). PLoS Negl Trop
Dis. 2013;7(10):e2463.
11. Reid IS. Mycobacterium ulcerans infection: a report of 13 cases at the Port
Moresby General Hospital, Papua. Med J Aust. 1967;1(9):427–31.
12. Kiiza AM, Wood PB. Buruli ulcer in an 18-day-old baby. Trop Dr. 2012;42(1):48.
13. Tsukagoshi S, Dehn TC. Buruli ulcer in a nine-month-old boy. Ann R Coll
Surg Engl. 2012;94(7):e215–6.
14. Smith PG, Revill WD, Lukwago E, Rykushin YP. The protective effect of BCG
against Mycobacterium ulcerans disease: a controlled trial in an endemic
area of Uganda. Trans R Soc Trop Med Hyg. 1976;70(5–6):449–57.
15. Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, Guedenon A, et al.
Prophylactic effect of Mycobacterium bovis BCG vaccination against
Amoako et al. Journal of Medical Case Reports          (2019) 13:218 Page 4 of 5
osteomyelitis in children with Mycobacterium ulcerans disease (Buruli ulcer).
Clin Diagn Lab Immunol. 2002;9(6):1389–91.
16. Phillips RO, Phanzu DM, Beissner M, Badziklou K, Luzolo EK, Sarfo FS, et al.
Effectiveness of routine BCG vaccination on Buruli ulcer disease: a case-
control study in the Democratic Republic of Congo, Ghana and Togo. PLoS
Negl Trop Dis. 2015;9(1):e3457.
17. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, et al. Clinical efficacy
of combination of rifampin and streptomycin for treatment of Mycobacterium
ulcerans disease. Antimicrob Agents Chemother. 2010;54(9):3678–85.
18. Phillips RO, Sarfo FS, Abass MK, Abotsi J, Wilson T, Forson M, et al. Clinical
and bacteriological efficacy of rifampin-streptomycin combination for two
weeks followed by rifampin and clarithromycin for six weeks for treatment
of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2014;
58(2):1161–6.
19. Klis S, Stienstra Y, Phillips RO, Abass KM, Tuah W, van der Werf TS. Long
term streptomycin toxicity in the treatment of Buruli ulcer: follow-up of
participants in the BURULICO drug trial. PLoS Negl Trop Dis. 2014;8(3):e2739.
20. Yeboah-Manu D, Kpeli GS, Ruf MT, Asan-Ampah K, Quenin-Fosu K, Owusu-
Mireku E, et al. Secondary bacterial infections of Buruli ulcer lesions before
and after chemotherapy with streptomycin and rifampicin. PLoS Negl Trop
Dis. 2013;7(5):e2191.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Amoako et al. Journal of Medical Case Reports          (2019) 13:218 Page 5 of 5
